PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Clinical Trials
5.0k
Trial Phases
6 Phases
Drug Approvals
69
Drug Approvals
Rimegepant Sulfate Orally Disintegrating Tablets
- Product Name
- 乐泰可
- Approval Number
- 国药准字HJ20240004
- Approval Date
- Jan 23, 2024
Ritlecitinib Tosylate Capsules
- Product Name
- 乐复诺
- Approval Number
- 国药准字HJ20230118
- Approval Date
- Oct 18, 2023
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (3916 trials with phase data)• Click on a phase to view related trials
A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.
- First Posted Date
- 2025-09-09
- Last Posted Date
- 2025-09-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 50
- Registration Number
- NCT07161687
A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060
- Conditions
- Healthy Adults
- Interventions
- First Posted Date
- 2025-09-08
- Last Posted Date
- 2025-09-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 28
- Registration Number
- NCT07160738
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
- Conditions
- Healthy
- Interventions
- Biological: Multivalent Group B streptococcus vaccineBiological: PlaceboBiological: Prevenar 20
- First Posted Date
- 2025-09-08
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6000
- Registration Number
- NCT07160244
- Locations
- 🇺🇸
Velocity Clinical Research, Covington, Covington, Louisiana, United States
🇺🇸Virginia Physicians For Women (VPFW), North Chesterfield, Virginia, United States
🇺🇸Clinical Research Partners, LLC, Richmond, Virginia, United States
A Study to Learn How the Study Medicine Called Etrasimod is Taken up Into Blood and Breastmilk of Healthy Breastfeeding Women
- First Posted Date
- 2025-09-03
- Last Posted Date
- 2025-09-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 8
- Registration Number
- NCT07153159
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région de, Belgium
A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice.
- First Posted Date
- 2025-09-03
- Last Posted Date
- 2025-09-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3000
- Registration Number
- NCT07152119
- Prev
- 1
- 2
- 3
- 4
- 5
- 639
- Next
News
Enveda Biosciences Raises $150M Series D to Advance AI-Driven Drug Discovery Platform
Enveda Biosciences secured $150 million in Series D funding led by Premji Invest to advance its AI-powered drug discovery platform that mines natural molecules for therapeutic development.
Radiance Biopharma Secures Exclusive License for First-in-Class Bispecific ADC Targeting c-MET and EGFR
Radiance Biopharma has signed an exclusive licensing agreement with Novatim for RB-601™, a first-in-class bispecific nanobody ADC targeting c-MET and EGFR receptors.
Biohaven Prepares for Potential First-in-Class Spinocerebellar Ataxia Drug Launch as FDA Decision Looms
Biohaven's Vyglxia could become the first approved treatment for spinocerebellar ataxia, a rare genetic brain disorder affecting movement and coordination, with FDA decision expected between October and December.
Olema Oncology and Pfizer Launch Phase 1b/2 Trial Combining Palazestrant with Atirmociclib for ER+/HER2- Metastatic Breast Cancer
Olema Oncology and Pfizer have announced a new clinical trial collaboration to evaluate the combination of palazestrant and atirmociclib in approximately 35 patients with ER+/HER2- metastatic breast cancer.
FDA Approves Pfizer-BioNTech LP.8.1-Adapted COVID-19 Vaccine for High-Risk Populations
The FDA approved Pfizer-BioNTech's LP.8.1-adapted monovalent COVID-19 vaccine on August 27 for adults 65 and older and individuals aged 5-64 with high-risk conditions.
ACROBiosystems and DAAN Biotherapeutics Form Strategic Alliance to Accelerate Precision Immuno-Oncology Development
ACROBiosystems and DAAN Biotherapeutics signed a strategic MOU to establish a multi-faceted collaboration framework for developing precision immunotherapies targeting drug-resistant cancers.
Lilly's Verzenio Demonstrates Significant Overall Survival Benefit in High-Risk Early Breast Cancer
Eli Lilly's Verzenio plus endocrine therapy demonstrated statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone in patients with HR+, HER2-, node-positive, high-risk early breast cancer.
Controlled Release Drug Delivery Market Expands with Major Pharma Investment in Precision Medicine Technologies
Major pharmaceutical companies including AbbVie, AstraZeneca, and Merck are actively developing controlled drug release systems to enhance treatment of chronic diseases, cancer, and neurological disorders.
Bristol Myers Squibb to Present New Cardiovascular Data at ESC Congress 2025, Including Breakthrough Non-Obstructive HCM Trial Results
Bristol Myers Squibb will present new clinical and real-world data for Camzyos (mavacamten) and Eliquis (apixaban) at the European Society of Cardiology Congress 2025 in Madrid.
Influenza Pipeline Surges with 120+ Therapies as Moderna, AstraZeneca Lead Innovation Wave
The global influenza pipeline has expanded to include 120+ companies developing 120+ treatment therapies, with breakthrough innovations spanning vaccines, antibodies, and combination therapies.